Clinical trial rules brought forward in Denmark
This article was originally published in Clinica
Executive Summary
Problems encountered in Denmark with Boneloc bone cement have prompted the country's National Board of Health to bring forward the full implementation of the EU Medical Device Directive rules on clinical trials. Boneloc, a cement used to secure artificial hips and manufactured in Denmark by Polymers Reconstructive (a Biomet subsidiary), was associated with an abnormally high surgery revision rate earlier this year (see Clinica No 650/51, p 2). It was alleged to have crumbled in a large number of cases.
You may also be interested in...
FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility
The US FDA’s device center has unveiled a new public dataset designed to assist chemistry laboratories in ensuring the robustness of chemical characterization methods used to assess the biocompatibility of medical devices.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.